Maryland Heights, MO, April 19, 2017 --(PR.com
)-- The global pulmonary drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global pulmonary drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global pulmonary drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Browse Pulmonary Drugs Market by Drug Class (Anticholinergics, Antihistamines, Combination Drugs, Inhaled Corticosteroids, Long-Acting Beta2-Agonists, Short-Acting Beta2-Agonists, Vasodilators, Antibiotics, Antileukotrienes, Enzymes, MAbs), Application (Allergic Rhinitis, Asthma & COPD, Cystic Fibrosis, Pulmonary Arterial Hypertension, Others), Distribution Channel (Drug Stores, E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/pulmonary-drugs-market/
The global pulmonary drugs market segmentation is based on drug class (anticholinergics, antihistamines, combination drugs, inhaled corticosteroids, long-acting beta2-agonists, short-acting beta2-agonists, vasodilators, antibiotics, antileukotrienes, enzymes, MAbs), application (allergic rhinitis, asthma & COPD, cystic fibrosis, pulmonary arterial hypertension, others), distribution channel (drug stores, e-commerce, hospital pharmacies, retail pharmacies).
Major players operating in the global pulmonary drugs market and profiled in this report include Actelion Pharmaceuticals, Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.
1. Drug Class
1.3. Combination Drugs
1.4. Inhaled Corticosteroids (ICS)
1.5. Long-Acting Beta2-Agonists (LABA)
1.6. Short-Acting Beta2-Agonists (SABA)
1.8. Others (Antibiotics, Antileukotrienes, Enzymes, MAbs, etc.)
2.1. Allergic Rhinitis
2.2. Asthma & COPD
2.3. Cystic Fibrosis
2.4. Pulmonary Arterial Hypertension
3. Distribution Channel
3.1. Drug Stores
3.3. Hospital Pharmacies
3.4. Retail Pharmacies
4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World
5. Company Profiles
5.1. Actelion Pharmaceuticals, Inc.
5.2. AstraZeneca plc
5.3. Bayer AG
5.4. Boehringer Ingelheim GmbH
5.5. F. Hoffmann-La Roche Ltd.
5.6. GlaxoSmithKline plc
5.7. Merck & Co., Inc.
5.8. Novartis AG
5.9. Sunovion Pharmaceuticals, Inc.
5.10. Teva Pharmaceutical Industries Ltd.
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043